Skip to content

Study · Not a test of the peptide alone · 1990

4 results

A non-opioid pattern characterizes inhibition of growth hormone releasing peptide binding by dynorphin-related peptides.

Codd EE, Aloyo VJ, Walker RF

Neuropeptides1 Mar 1990Cited by 4 (Europe PMC)

PMID1979153 (opens in a new tab)DOI10.1016/0143-4179(90)90144-n (opens in a new tab)PepBankPUB-01979153
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 01LabNot a test of GHRP-6 aloneIn vitro (cell-free)Mechanism

    In binding assays, dynorphin A potently inhibited SK&F 110679 binding.

    In plain wordsIn lab tests, dynorphin A strongly inhibited GHRP‑6 binding.

    Peptide
    GHRP-6
    Outcome
    DecreaseDynorphin inhibition of binding
    Study

    n: not reported in source

    3H-SK&F 110679 binding assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    In the present study, dynorphin A was a potent inhibitor of SK&F 110679 binding.
    1 context sentence
    Summary · context
    GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-LysNH2; SK&F 110679) is a hexapeptide that specifically releases growth hormone.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02LabNot a test of GHRP-6 aloneIn vitro (cell-free)Mechanism

    Structure-activity studies suggested a non-opioid interaction between SK&F 110679 and dynorphin.

    In plain wordsIn lab tests, the interaction between GHRP‑6 and dynorphin appeared non-opioid.

    Peptide
    GHRP-6
    Outcome
    Not applicableNon-opioid binding interaction
    Study

    n: not reported in source

    3H-SK&F 110679 binding assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    However, detailed structure-activity studies using dynorphin-related compounds suggest that the interaction between SK&F 110679 and dynorphin was non-opioid in nature.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 03LabNot a test of GHRP-6 aloneIn vitro (cell-free)Mechanism

    In binding assays, des-Tyr-dynorphin was virtually as potent as intact dynorphin at inhibiting GHRP‑6 binding.

    In plain wordsIn lab tests, des-Tyr-dynorphin inhibited GHRP‑6 binding about as strongly as intact dynorphin.

    Peptide
    GHRP-6
    Outcome
    Not applicableDes-Tyr-dynorphin binding inhibition
    Study

    n: not reported in source

    3H-SK&F 110679 binding assay
    Comparator
    Intact dynorphin
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    The non-opioid peptide des-Tyr-dynorphin was virtually as potent an inhibitor of 3H-SK&F 110679 binding as the intact dynorphin peptide.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 04LabNot a test of GHRP-6 aloneIn vitro (cell-free)Mechanism

    In binding assays, U-50,488 weakly inhibited GHRP‑6 binding.

    In plain wordsIn lab tests, U-50,488 weakly inhibited GHRP‑6 binding.

    Peptide
    GHRP-6
    Outcome
    DecreaseU-50,488 binding inhibition
    Study

    n: not reported in source

    3H-SK&F 110679 binding assay
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    Additionally, the non-peptide, kappa selective ligand U-50,488 was a very weak inhibitor of 3H-SK&F 110679 binding.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:59 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.